Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 3/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.32 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722765 | 0.73 | NR4A2 (0.34) | PSMB8PSMB5NR4A2SOS2CASP6 | |
| SCHEMBL2211013 | 0.73 | ALDH1A1 (0.35) | PSMB8PSMB5NR4A2SOS2CASP6 | |
| SCHEMBL29767254 | 0.73 | NR4A2 (0.34) | PSMB8PSMB5NR4A2SOS2CASP6 | |
| SCHEMBL723857 | 0.71 | NR4A2 (0.33) | PSMB8PSMB5NR4A2SOS2CASP6 | |
| SCHEMBL30765207 | 0.71 | NR4A2 (0.33) | PSMB8PSMB5NR4A2SOS2CASP6 | |
| SCHEMBL4758600 | 0.69 | NR4A2 (0.32) | NR4A2SOS2CASP6 | |
| SCHEMBL18348153 | 0.69 | NR4A2 (0.35) | NR4A2SOS2CASP6 | |
| SCHEMBL1849392 | 0.69 | RECQL (0.38) | NR4A2SOS2CASP6 | |
| SCHEMBL18340397 | 0.69 | NR4A2 (0.32) | NR4A2SOS2CASP6 | |
| SCHEMBL722060 | 0.68 | CYP1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981891-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2137177-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, CDK1 | PSMB8 2212/4885PSMB5 3647/4885LRRK2 362/4885 |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | PSMB8 2212/4885PSMB5 3647/4885LRRK2 362/4885 |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | PSMB8 2212/4885PSMB5 3647/4885LRRK2 362/4885 |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | PSMB8 29/4885PSMB5 74/4885LRRK2 1645/4885 |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | PSMB8 2212/4885PSMB5 3647/4885LRRK2 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.